By: Jay Kt
The founder of Auralis Biotech helps scientists, biotech and diagnostics innovators, and investors turn research into commercial momentum.
For Dr. Giuseppina Sannino, science has never been just a profession. It has been a language, an identity, a challenge, and a calling. As founder and CEO of Auralis Biotech, she stands at one of the most important intersections in the life sciences: the space between the laboratory and the market.
It is a space where many brilliant technologies fail. Not because the science is weak, but because the people behind it are rarely taught how to communicate it, commercialize it, position it, validate it, and bring it to the customers, partners, investors, and acquirers who can help it create impact.
That is the gap Dr. Sannino built Auralis Biotech to close.
“I stand in the gap between two worlds that rarely speak the same language: the lab and the market,” she says. “Good science dies in that gap every day, not because it is weak, but because no one translates it into something a customer can actually adopt.”
A molecular biologist with a PhD in cancer biology and more than a decade of experience commercializing tools across diagnostics and the life sciences, Dr. Sannino combines scientific depth, commercial instinct, and hands-on execution. Her work is not limited to strategy from a distance. One week, she may be turning a farm into a temporary laboratory; the next, building a partnership at a trade fair that carries a technology into a new market.
Through Auralis Biotech, she supports companies across the full commercial journey: Build, Grow, Scale, and Exit. That work spans positioning, go-to-market planning, fractional business development, scientific marketing, European market entry, strategic partnerships, and investor and acquirer readiness.
Beneath the services is a deeper mission. Dr. Sannino wants to change the way scientists think about commercialization, because to her, selling science is not manipulation. It is stewardship.
“When your technology genuinely helps people, getting it to them is not a compromise,” she says. “It is a duty.”
From Academia to Industry
For most of her life, Dr. Sannino did not imagine a career outside academia.
She grew up in Italy in a family with no academic background, no scientists at the dinner table, and no clear map toward a PhD. Yet she followed the path anyway, eventually earning a PhD in cancer biology from the University of Tübingen, magna cum laude, at the age of 27.
The academic dream seemed clear.
Then life forced a different question.
An autoimmune condition made bench work increasingly difficult and eventually pushed her away from the lab. For someone whose identity had been shaped around academic research, the transition was not simply professional. It was existential.
With her health shaken and her future unclear, Dr. Sannino flew to Bali alone for three weeks to understand who she was without the lab coat. On a beach there, a stranger described a life that sounded almost impossible to her at the time, building websites and working from anywhere rather than around a fixed location.
When she returned home, she taught herself basic HTML and loved it, though she could not yet see how that world could connect to her passion for science. Only later would she realize that the Bali conversation had quietly planted the first seed of her future company.
Still searching, she faced rejection after rejection until a sales role in Germany changed everything. The hiring manager called because she was the only scientist who had applied, believing a scientist-to-scientist conversation with customers might prove more valuable than a traditional sales pitch, which became the turning point.
“In business development, I found I was doing more science, and reaching more people, than I ever had at the bench,” Dr. Sannino says.
The Problem Auralis Biotech Was Built to Solve
Dr. Sannino’s frustration with the market began long before she founded Auralis.
As a scientist and customer, she disliked coordinating multiple suppliers to solve one problem. Each company offered a slice of the solution, but few understood the full scientific and commercial picture, and salespeople often had no lab experience, which made trust harder to build.
Later, working inside young companies across business development, technical support, marketing, sales, and management, she saw the same issue from the company side. Customers did not want to be passed from sales to R&D to marketing to management. They wanted one trusted person who could understand the science, coordinate the moving parts, and help them decide well.
That insight shaped Auralis as an embedded commercial partner, not an outside vendor. It gives science-led companies senior commercial support to understand the technology, refine strategy, build connections, and adapt as they grow.
Auralis Biotech serves growth-stage biotech and diagnostics companies, firms entering Europe, investors scouting European assets, and early-stage scientist-founders learning how to commercialize their work.
Its purpose is simple: turn laboratory value into commercial momentum without losing the integrity of the science.
A Scientist’s Approach to Commercialization
What makes Auralis different is how it thinks, not only what it offers.
Dr. Sannino approaches commercialization not as a generic sales function but as decision-enablement.
A commercial conversation, in her view, has done its job when the other person can make a better decision, whether or not they buy.
That philosophy matters in a technical industry where buyers are sophisticated, skeptical, and tired of inflated promises. They do not want personality-driven sales scripts. They want evidence, clarity, and honesty.
This is why Dr. Sannino challenges the misconception that scientists make poor salespeople.
“In truth, they have an unfair advantage,” she says. “They understand the technology, they trust evidence, and they are honest about a product’s limits, which is exactly what a technical buyer is desperate to hear.”
In a previous role, Dr. Sannino built an EMEA business from scratch as the company’s only person in Europe. Without formal sales training, she created a distributor network across Europe and Africa and helped drive the company’s international expansion.
For her, the lesson was clear: commercial success in science does not require pressure. It requires method, integrity, and the ability to translate technical value into customer relevance.
A Defining COVID-Era Success Story
One of the clearest examples came in late 2019, just as COVID-19 changed the world.
She had just left academia and joined a company with an alternative RNA extraction method. When global suppliers struggled to produce enough RNA extraction kits, the company’s method could be made faster, but it was research-use-only and had not been tested in that specific diagnostic context.
Rather than approaching customers as a salesperson, she approached them as a scientist.
She brought customers in Italy, Spain, and the Czech Republic into a working group, each with different technologies, samples, and needs. Together, they worked to validate and adapt the method for detecting the virus more quickly.
They met weekly. They solved problems together. The dynamic felt less like vendor and buyer and more like one scientific team working toward a shared outcome.
The Italian group eventually built its COVID assay, the study was published with Dr. Sannino’s contribution acknowledged, and the work later helped seed a startup spinout.
Dr. Sannino also became the only commercial person in the company to win a high-volume order during the crisis.
Her explanation is simple: she did not walk in to sell. She walked in to solve.
That same instinct now shapes her work with Auralis Biotech, including her support for Trustech Diagnostics and its EliChip platform.
Building Auralis With Fear, Not Without It
The story of Auralis is also a story of fear.
Years before founding the company, a customer had asked Dr. Sannino to start a business with her. They had gone as far as creating a name and logo. Then fear took over, and Dr. Sannino stayed in the safety of her job.
That decision stayed with her, and over time it turned into a quiet obsession: one day she would build something of her own. With Auralis, she finally did.
She taught herself the machinery of entrepreneurship: invoices, taxes, website development, investor pitching, and the daily reality of running a company. It was not glamorous, but it was hers.
The founder who once could not imagine a work-from-anywhere life in science now runs her own company, creating scientific web content, commercial strategy, and market pathways for biotech innovators while living near the sea.
“I am not fearless,” she says. “I carry a great deal of fear. I just refuse to let it make my decisions.”
Leadership Built on Trust and Integrity
Dr. Sannino describes her leadership style as servant leadership.
She leads from the front and in service of others, and will not ask a client or collaborator to do something she has not done herself, often while afraid.
Her leadership is also shaped by emotional intelligence. She believes people give their best when they feel understood rather than managed, and that belief shows up in her transparency: if she does not have the right skill, answer, or data, she says so.
Her values are equally direct: integrity, stewardship, kindness, resilience, and scientific rigor.
For Dr. Sannino, integrity means honesty even when it costs revenue, stewardship means taking responsibility for bringing useful science to the people who need it, and scientific rigor means never inventing a number, source, or result.
Together, she sees them as “the scientist’s contract”: tell the truth and be useful.
The most important lesson she has learned is the power of trust. Her first manager in industry saw potential in her when no one else would look past a CV with no commercial experience, and that trust gave her the confidence to cross from academia into business. Now, she tries to offer the same to others.
“A leader’s real job is to see people for what they can become, not only for what they have already done,” she says.
The Future of Biotech Commercialization
Looking ahead, Dr. Sannino believes the life sciences industry is underestimating two major opportunities.
The first is AI, but not as a shortcut.
She sees AI as a tool that helps people think more widely and build more complete solutions. Used badly, it skips the work. Used properly, it supports deeper thinking, while the human remains responsible for what is true.
The second overlooked opportunity is commercial skill itself.
The industry invests heavily in science, but far less in training scientists to carry it to market. For Dr. Sannino, this is a serious gap. Companies that treat commercial ability as a core scientific skill, not a separate function added later, will be better positioned for the next decade.
Her vision for the next three to five years is for Auralis Biotech to become the trusted partner for startups and corporations that must communicate their science clearly and carry their technologies to market credibly.
The destination, she says, does not change.
More biology turned into value, ethically.
A Message for Scientists and Founders
If readers remember one message from Dr. Sannino’s journey, it is this: believe in yourself, and treat challenges as growth, not as verdicts.
Her life shows how setbacks can lead to more aligned paths. Losing the academic route she once envisioned helped her create a broader scientific impact, while her health challenges moved her from the bench to work that could support more people and more science.
The young woman, once told to lower her ambitions, now runs a company helping scientists worldwide turn biology into value.
And for Dr. Sannino, that is the real achievement.
Not the title.
Not the company name.
Not even the milestones.
The achievement is refusing to let other people’s doubts draw the borders of her life, and then building a company that helps other scientists refuse the same.
To learn more, visit the Auralis Biotech website. Connect with Dr. Giuseppina Sannino on her LinkedIn profile, or follow the Auralis Biotech company page on LinkedIn.
